Medtronic plc

Alpha Score of 39 reflects weak overall profile with moderate value, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.

Medtronic plc is a global leader in medical technology, developing and manufacturing devices and therapies that address over 70 health conditions. The company operates across four main portfolios: Cardiovascular, which includes cardiac ablation solutions, rhythm management, surgery, coronary and renal denervation, mechanical circulatory support, peripheral vascular health, structural heart and aortic products; Diabetes, offering therapies and services for insulin-dependent individuals with Type 1 and Type 2 diabetes; Medical Surgical, encompassing surgical endoscopy and acute care and monitoring; and Restorative Therapies, covering cranial and spinal technologies, neuromodulation, neurovascular, pelvic health, gastric therapies, and ear, nose, and throat solutions. Medtronic plc produces innovative products such as implantable pacemakers, cardioverter-defibrillators, spinal cord stimulators, insulin pumps, and remote monitoring systems, serving patients in hospitals, homes, and surgical settings worldwide. Founded in 1949 and legally headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota, it focuses on advancing healthcare through minimally invasive therapies, disease management, and patient monitoring technologies in more than 150 countries.